dcr-aud
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 21, 2021 (NCT05021640)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Aldehyde dehydrogenaseANTISENSE INHIBITOR
ALDH2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05845398 | Phase 1 | Jan 29, 2023 | Novo Nordisk, Parexel |
| NCT05021640 | Phase 1 | Sep 21, 2021 | Dicerna Pharmaceuticals, Inc., Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Parexel | For profit | 2 | 0 | 1 | 2021 |
| Dicerna Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1